With Few Questions From FDA, Cinryze Seems Set For Smooth Committee Review
FDA will review Cinryze only for prophylaxis of hereditary angioedema at Blood Products advisory panel meeting May 2, leaving open the possibility of a split indication.
FDA will review Cinryze only for prophylaxis of hereditary angioedema at Blood Products advisory panel meeting May 2, leaving open the possibility of a split indication.